Fibrocell Science Inc (NYSEMKT:FCSC) was trading lower by -0.05 points or -1.00% to $4.96. So far, around 40.84 million shares have changed hands in this session. After opening at $5.01, the stock hit as high as $5.23. However, it traded between $3.03 and $7.20 over the last twelve months. Fibrocell Science, Inc. is an aesthetic and therapeutic development stage biotechnology company focused on developing skin and tissue rejuvenation products. The Company’s clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burn scars with a patient’s own, or autologous, fibroblast cells produced by its Fibrocell process. Fibrocell Science Inc (NYSEMKT:FCSC), shares after opening at $5.01 moved to $5.14 on last trade day and at the end of the day closed at $4.65. Company price to sales ratio in past twelve months was calculated as 949.53 and price to cash ratio as 3.17. Fibrocell Science Inc (NYSEMKT:FCSC), showed a negative weekly performance of 12.59%.
On April, 4, 2014, Escalon Medical Corp. (NASDAQ:ESMC), announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its new tablet-based ultrasound imaging system, the Sonomed Escalon VuPad™. Escalon Medical Corp. (NASDAQ:ESMC), shares advanced 10.46% in last trading session and ended the day on $1.69. Escalon Medical Corp. (NASDAQ:ESMC), return on equity ratio is recorded as -27.80% and its return on assets is -14.70%. Escalon Medical Corp. (NASDAQ:ESMC), yearly performance is 57.94%.
Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares decreased 7.21% to $3.73. The company on Mar. 28 announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400. The trial met its primary objective as all treatments were well tolerated with no treatment related discontinuation, serious adverse events or dose reductions. Idera Pharmaceuticals Inc (NASDAQ:IDRA), shares moved down 7.71% in last trading session and was closed at $3.71, while trading in range of $ 3.52 – 4.07. Idera Pharmaceuticals Inc (NASDAQ:IDRA), year to date (YTD) performance is -19.87%.
As of late, it has definitely been a great time to be an investor in Receptos Inc (RCPT – Snapshot Report). The stock has moved higher by 56.3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. Receptos Inc (NASDAQ:RCPT), weekly performance is -4.29%. On last trading day company shares ended up $37.93. Receptos Inc (NASDAQ:RCPT), distance from 50-day simple moving average (SMA50) is -15.39%. Analysts mean target Price for the company is $54.50.
Leave a Reply